KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBT (2017 - 2026)

Aquestive Therapeutics has reported EBT over the past 9 years, most recently at -$31.9 million for Q4 2025.

  • For Q4 2025, EBT fell 86.65% year-over-year to -$31.9 million; the TTM value through Dec 2025 reached -$83.8 million, down 89.77%, while the annual FY2025 figure was -$83.8 million, 89.77% down from the prior year.
  • EBT for Q4 2025 was -$31.9 million at Aquestive Therapeutics, down from -$15.4 million in the prior quarter.
  • Over five years, EBT peaked at $8.1 million in Q1 2023 and troughed at -$31.9 million in Q4 2025.
  • A 5-year average of -$13.0 million and a median of -$13.0 million in 2022 define the central range for EBT.
  • Biggest five-year swings in EBT: crashed 429.86% in 2021 and later surged 161.03% in 2023.
  • Year by year, EBT stood at -$28.9 million in 2021, then soared by 57.33% to -$12.4 million in 2022, then skyrocketed by 35.15% to -$8.0 million in 2023, then plummeted by 113.1% to -$17.1 million in 2024, then plummeted by 86.65% to -$31.9 million in 2025.
  • Business Quant data shows EBT for AQST at -$31.9 million in Q4 2025, -$15.4 million in Q3 2025, and -$13.5 million in Q2 2025.